Nkarta 

Nkarta 

Yahoo Finance • 2 months ago

Nkarta Posts Wider Loss In Q2; Provides Clinical Update On NKX019

(RTTNews) - Nkarta, Inc., (NKTX) a clinical-stage biotech company, posted its second quarter financial results, reflecting a wider net loss compared with the prior-year quarter, primarily attributed to higher operating expenses and lower o... Full story

Yahoo Finance • 3 months ago

Cyllene Therapeutics Expands Leadership Team to Support Corporate Growth and Clinical Product Development

Paris, France and New York, USA , July 23, 2026 (GLOBE NEWSWIRE) -- Alyssa Levin appointed to Board of Directors and as Chair of the Audit CommitteeClara Cambon-Thiebaud joins as VP, Regulatory AffairsCéline Breda joins as VP, Chemistry... Full story

Yahoo Finance • 4 months ago

Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference

SOUTH SAN FRANCISCO, Calif., June 26, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced... Full story

Yahoo Finance • 5 months ago

Nkarta GAAP EPS of -$0.37 in-line

* Nkarta press release [https://seekingalpha.com/pr/20512111-nkarta-reports-first-quarter-2026-financial-results-and-corporate-highlights] (NKTX [https://seekingalpha.com/symbol/NKTX]): Q1 GAAP EPS of -$0.37 in-line. * Nkarta had cash,... Full story

Yahoo Finance • 7 months ago

CD19 Inhibitors Market to Witness Significant Expansion During the Forecast Period (2025-2034) as Autoimmune and Oncology Pipelines Accelerate | DelveInsight

The CD19 inhibitors market is projected to expand substantially in the coming years. This growth is driven by a rising number of patients diagnosed with conditions such as NHL, ALL, NMOSD, IgG4-RD, SLE, multiple sclerosis, and other relate... Full story

Yahoo Finance • 8 months ago

Nkarta to Participate in March Investor Conferences

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced... Full story

Yahoo Finance • 10 months ago

Nkarta to Participate in Evercore Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Dec. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune diseases, today announced... Full story

Yahoo Finance • 11 months ago

Nkarta Reports Third Quarter 2025 Financial Results and Corporate Highlights 

Enrollment now underway in second dose-escalation cohort Deep B-cell depletion observed in all patients treated to date who received NKX019 with lymphodepletion using fludarabine and cyclophosphamide versus partial B-cell depletion in pati... Full story

Yahoo Finance • 11 months ago

Nkarta to Participate in November Investor Conferences

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the fol... Full story

Yahoo Finance • 12 months ago

Glomerulonephritis Market Projected to Surge by 2034 with Rising Demand for Targeted Therapies | DelveInsight

The glomerulonephritis market is witnessing steady growth driven by the increasing prevalence of chronic kidney diseases and improved diagnostic capabilities. Additionally, ongoing clinical trial activities and the launch of emerging thera... Full story

Yahoo Finance • 12 months ago

Nkarta Announces Poster Presentation at Upcoming American College of Rheumatology (ACR) Convergence Meeting

SOUTH SAN FRANCISCO, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune disease, today announced... Full story

Yahoo Finance • 12 months ago

OZK Crosses Below Key Moving Average Level

In trading on Thursday, shares of Bank OZK (Symbol: OZK) crossed below their 200 day moving average of $47.57, changing hands as low as $46.95 per share. Bank OZK shares are currently trading off about 6.9% on the day. The chart below sh... Full story

Yahoo Finance • last year

Nkarta to Participate in a September Investor Conference

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the fo... Full story

Yahoo Finance • last year

Nkarta Reports Second Quarter 2025 Financial Results and Corporate Highlights

Initial update for NKX019 in multiple autoimmune indications expected in second half of 2025Cash balance of $334.0 million on June 30, 2025, including cash, cash equivalents and investments, expected to fund operations into 2029 SOUTH SAN... Full story

Yahoo Finance • last year

Nkarta to Participate in the H.C. Wainwright “HCW@Home” Series

SOUTH SAN FRANCISCO, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the H.C... Full story

Yahoo Finance • last year

Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus

SOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune disease, today announced... Full story

Yahoo Finance • 2 years ago

Nkarta to Participate in an April Investor Conference

SOUTH SAN FRANCISCO, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investo... Full story

Yahoo Finance • 2 years ago

Nkarta Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Highlights

Differentiated development program includes two Nkarta clinical trials and two investigator-sponsored trials of NKX019 in rheumatic and neurological diseasesInitial data for NKX019 in multiple autoimmune indications expected in second half... Full story

Yahoo Finance • 3 years ago

T. Rowe Price Investment Management, Inc. Reduces Stake in Nkarta Inc

Overview of the Recent Transaction T. Rowe Price Investment Management, Inc. (Trades, Portfolio), a renowned investment firm, has recently adjusted its investment in Nkarta Inc (NASDAQ:NKTX), a biopharmaceutical company. On October 31, 20... Full story

Yahoo Finance • 3 years ago

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Nkarta, Inc. (NASDAQ: NKTX) and Encourages Investors to Contact the Firm

PHILADELPHIA, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Nkarta, Inc. (NASDAQ: NKTX) (“Nkarta”) on behalf of the company’s investors. Since June 2023, shares of Nkarta’s common stock have decli... Full story